Paper Details

  1. Home
  2. Paper Details

A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C.

Author: AlcaláA, AlonsoC, BesalduchJ, García-CondeJ, GarijoJ, GomisF, GutierrezM, GuzmánM C, MontserratE, MoraledaJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

This study compared two chemotherapy regimens for 96 patients with chronic lymphocytic leukemia (CLL): chlorambucil plus prednisone (CLR + PDN) and cyclophosphamide, melphalan, and prednisone (CMP). CLR + PDN resulted in a higher response rate (75%) compared to CMP (54.5%). While more patients in stage B CLL responded to treatment compared to those with stage C, this difference was not statistically significant. There was no significant difference in survival between the two treatment groups. The study concludes that both regimens are effective for CLL, with CLR + PDN having a slightly higher response rate.
Paper Details　
Original Abstract of the Article :
Ninety-six previously untreated patients (67 males/29 females; mean age: 63 years; range: 46-84) with CLL in stage B (62 cases) or C (34 cases) were randomized to be treated with either chlorambucil (0.4 mg/kg orally days 5 and 6) plus prednisone (60 mg/m2 orally days 1 to 4) (CL + PDN) every 2 week...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3065738

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: Exploring Treatment Options in the Desert

Chronic lymphocytic leukemia (CLL), like a desert sandstorm, can be a challenging and potentially life-threatening condition. This research, like a team of scientists seeking effective treatment strategies, compares two different chemotherapy regimens for CLL in stages B and C.

Chlorambucil Plus Prednisone vs. Cyclophosphamide, Melphalan, and Prednisone: A Comparison in the Desert of CLL Treatment

The researchers conducted a randomized trial, comparing chlorambucil plus prednisone (CL+PDN) to cyclophosphamide, melphalan, and prednisone (CMP) in 96 patients with CLL. The study found that both regimens showed promising results, with higher response rates observed in stage B compared to stage C. Although the difference in survival rates between the two regimens was not statistically significant, this research provides valuable insights into the potential effectiveness of these treatment options for CLL.

Chronic Lymphocytic Leukemia: Navigating the Sands of Treatment

CLL, like a desert landscape, can be unpredictable and difficult to navigate. This research, like a compass guiding us through the complexities of CLL treatment, highlights the potential of different chemotherapy regimens in managing this challenging condition. It emphasizes the importance of careful consideration of patient characteristics and disease stage when selecting the most appropriate treatment approach.

Dr. Camel's Conclusion

The study, like a caravan traversing a desert landscape, reveals the potential of different chemotherapy regimens in the treatment of CLL. This research serves as a reminder that the journey through CLL can be complex and require careful navigation, but with the right tools and strategies, hope for a brighter future can be found.

Date :
  1. Date Completed 1989-03-16
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3065738

DOI: Digital Object Identifier

3065738

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.